236 related articles for article (PubMed ID: 35868257)
1. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
Drexler R; Schüller U; Eckhardt A; Filipski K; Hartung TI; Harter PN; Divé I; Forster MT; Czabanka M; Jelgersma C; Onken J; Vajkoczy P; Capper D; Siewert C; Sauvigny T; Lamszus K; Westphal M; Dührsen L; Ricklefs FL
Neuro Oncol; 2023 Feb; 25(2):315-325. PubMed ID: 35868257
[TBL] [Abstract][Full Text] [Related]
2. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
4. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
5. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
6. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
[TBL] [Abstract][Full Text] [Related]
7. Extent of resection affects prognosis for patients with glioblastoma in non-eloquent regions.
Kow CY; Kim BJH; Park TI; Chen JCC; Vong CK; Kim JY; Shim V; Dragunow M; Heppner P
J Clin Neurosci; 2020 Oct; 80():242-249. PubMed ID: 33099354
[TBL] [Abstract][Full Text] [Related]
8. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Bloch O; Han SJ; Cha S; Sun MZ; Aghi MK; McDermott MW; Berger MS; Parsa AT
J Neurosurg; 2012 Dec; 117(6):1032-8. PubMed ID: 23039151
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients.
Ricklefs FL; Drexler R; Wollmann K; Eckhardt A; Heiland DH; Sauvigny T; Maire C; Lamszus K; Westphal M; Schüller U; Dührsen L
Neuro Oncol; 2022 Nov; 24(11):1886-1897. PubMed ID: 35511473
[TBL] [Abstract][Full Text] [Related]
10. Pseudoprogression in glioblastoma patients: the impact of extent of resection.
Park HH; Roh TH; Kang SG; Kim EH; Hong CK; Kim SH; Ahn SS; Lee SK; Choi HJ; Cho J; Kim SH; Lee KS; Suh CO; Chang JH
J Neurooncol; 2016 Feb; 126(3):559-66. PubMed ID: 26608521
[TBL] [Abstract][Full Text] [Related]
11. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
12. Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery.
Shah AS; Sylvester PT; Yahanda AT; Vellimana AK; Dunn GP; Evans J; Rich KM; Dowling JL; Leuthardt EC; Dacey RG; Kim AH; Grubb RL; Zipfel GJ; Oswood M; Jensen RL; Sutherland GR; Cahill DP; Abram SR; Honeycutt J; Shah M; Tao Y; Chicoine MR
J Neurosurg; 2020 Oct; ():1-10. PubMed ID: 33035996
[TBL] [Abstract][Full Text] [Related]
13. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma surgery with and without intraoperative MRI at 3.0T.
Napolitano M; Vaz G; Lawson TM; Docquier MA; van Maanen A; Duprez T; Raftopoulos C
Neurochirurgie; 2014 Aug; 60(4):143-50. PubMed ID: 24975207
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation.
Marchi F; Sahnane N; Cerutti R; Cipriani D; Barizzi J; Stefanini FM; Epistolio S; Cerati M; Balbi S; Mazzucchelli L; Sessa F; Pesce GA; Reinert M; Frattini M
Front Oncol; 2019; 9():1569. PubMed ID: 32039032
[No Abstract] [Full Text] [Related]
19. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes.
Kessler T; Berberich A; Sadik A; Sahm F; Gorlia T; Meisner C; Hoffmann DC; Wick A; Kickingereder P; Rübmann P; Bendszus M; Opitz C; Weller M; van den Bent M; Stupp R; Winkler F; Brandes A; von Deimling A; Platten M; Wick W
Cancer Med; 2020 Nov; 9(22):8373-8385. PubMed ID: 32991787
[TBL] [Abstract][Full Text] [Related]
20. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
